In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics, provides an update on the progress of Coya 302 as a treatment for ALS.
Coya Therapeutics CEO Discusses Recent Data Discovery from a Study of Coya 302, a Potential Treatment for ALS